Delving into the Latest Updates on Oct-AAVP-TNF with Synapse

Overview

Basic Info

Drug Type

Gene therapy

Synonyms-

Target

SSTR2 x TNF

Mechanism

SSTR2 antagonists(Somatostatin receptor 2 antagonists), TNF inhibitors(Tumor necrosis factor inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]

Active Indication

Neuroendocrine tumor of pancreas

Inactive Indication-

Originator Organization

The University of New Mexico

Active Organization

The University of New Mexico

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

SignificanceThere are literally thousands of biologically active, clinically relevant peptide motifs in mammalian species. Surprisingly, however, despite this abundance of potential peptide reagents for ligand-directed delivery, applications for targeted gene therapy are generally lacking. Here we used a hybrid AAV/phage (AAVP) vector for octreotide ligand-directed therapeutic gene delivery to pancreatic neuroendocrine tumors in a transgenic mouse model that faithfully recapitulates the cognate human disease. This platform is readily available for a translational clinical trial. In a broader context, this proof-of-concept work establishes a unique targeting paradigm in which existing ligand/receptors may be exploited in nature while minimizing or eliminating several rate-limiting steps of conventional phage display library selection that require cumbersome experimental discovery work.

100 Deals associated with Oct-AAVP-TNF

Login to view more data